Copy number neutral LOH detected in resistant CML samples
| ID . | Chromosome . | Starting position . | Ending position . | Length, Mb . | Candidate genes . | Treatment . | Disease status . |
|---|---|---|---|---|---|---|---|
| 41-R | 1p36 | 825,852 | 18193698 | 17.36 | RERE, ENO-1 | Imatinib | Unknown |
| 43-R | 1p36 | 18,323,554 | 52881039 | 34.55 | RERE, ENO-1 | Imatinib | Unknown |
| 5 | 2q | 182983286 | 242712341 | 59.73 | Imatinib | CML | |
| 31 | 3q | 123593611 | 136239458 | 12.65 | HU, imatinib | CML in hematologic remission | |
| 36-R | 5p | 29256280 | 35121357 | 5.87 | HU, imatinib | CML in hematologic remission | |
| 41-R | 6q | 109232515 | 124242464 | 15.01 | FYN | Imatinib | Unknown |
| 36-R | 6q | 139970070 | 153644361 | 13.67 | HU, imatinib | CML in hematologic remission | |
| 41-R | 11p15 | 8895510 | 19285890 | 10.39 | Imatinib | Unknown | |
| 42-R* | 17q | 23581904 | 78599918 | 55.01 | STAT3, STAT5A/B | HU, imatinib | CML in acceleration |
| 27 | 19q13 | 58448005 | 63731511 | 5.28 | BIRC8, AURKC | Imatinib | Unknown |
| 10 | 19q13 | 38496239 | 63700378 | 25.2 | BIRC8, AURKC | Imatinib, dasatinib, HU | CML in hematologic remission |
| ID . | Chromosome . | Starting position . | Ending position . | Length, Mb . | Candidate genes . | Treatment . | Disease status . |
|---|---|---|---|---|---|---|---|
| 41-R | 1p36 | 825,852 | 18193698 | 17.36 | RERE, ENO-1 | Imatinib | Unknown |
| 43-R | 1p36 | 18,323,554 | 52881039 | 34.55 | RERE, ENO-1 | Imatinib | Unknown |
| 5 | 2q | 182983286 | 242712341 | 59.73 | Imatinib | CML | |
| 31 | 3q | 123593611 | 136239458 | 12.65 | HU, imatinib | CML in hematologic remission | |
| 36-R | 5p | 29256280 | 35121357 | 5.87 | HU, imatinib | CML in hematologic remission | |
| 41-R | 6q | 109232515 | 124242464 | 15.01 | FYN | Imatinib | Unknown |
| 36-R | 6q | 139970070 | 153644361 | 13.67 | HU, imatinib | CML in hematologic remission | |
| 41-R | 11p15 | 8895510 | 19285890 | 10.39 | Imatinib | Unknown | |
| 42-R* | 17q | 23581904 | 78599918 | 55.01 | STAT3, STAT5A/B | HU, imatinib | CML in acceleration |
| 27 | 19q13 | 58448005 | 63731511 | 5.28 | BIRC8, AURKC | Imatinib | Unknown |
| 10 | 19q13 | 38496239 | 63700378 | 25.2 | BIRC8, AURKC | Imatinib, dasatinib, HU | CML in hematologic remission |
Copy number alterations (CNAs) in TKI-resistant samples without a matched diagnostic sample are shown with plain numbers in the column “ID.” CNAs in TKI-resistant samples with a matched diagnostic sample with the CNAs being present in both the diagnostic sample and the resistant sample are shown with numbers + “R” in the column “ID.” CNAs which were newly acquired in matched resistant samples compared to the diagnostic samples are shown with numbers + “R*” in the column “ID.”
ID indicates patient ID; Starting position, start position of genomic lesion; Ending position, end position of genomic lesion; HU, hydroxyurea; DA, daunorubicin plus cytarabine; ICT, induction chemotherapy; and IFN, interferon-α.